NEWS
Heron Therapeutics Announces Preliminary, Unaudited Q4 and Full-Year 2025 Net Revenue; ZYNRELEF® Largest Contributor to Q4 Growth
Friday, 9th January at 9:29 am
CARY, N.C., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (NASDAQ: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced preliminary, unaudited fourth quarter and full-year 2025 net revenue.
"We are encouraged by the growth in Q4 2025, driven in particular by the momentum in our Acute Care franchise with ZYNRELEF® and APONVIE®," said Craig Collard, Chief Executive Officer of Heron. "In addition to our revenue growth, we are extremely pleased with the continued progress made across all aspects of our business throughout the past year."
Preliminary Fourth Quarter and Full Year 2025 Updates
Net revenue of approximately $40.5 million for the three months ended December 31, 2025.
ZYNRELEF® net revenue of approximately $12.5 million for the three months ended December 31, 2025.
APONVIE® net revenue of approximately $3.8 million for the three months ended December 31, 2025.
CINVANTI® net revenue of approximately $22.9 million for the three months ended December 31, 2025.
SUSTOL® net revenue of approximately $1.3 million for the three months ended December 31, 2025.
Net revenue of approximately $154.9 million for full-year 2025.
ZYNRELEF® delivered the largest quarter-over-quarter revenue increase within the portfolio in Q4 (up ~35% vs Q3 2025).
Friday, 9th January at 9:29 am
CARY, N.C., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (NASDAQ: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced preliminary, unaudited fourth quarter and full-year 2025 net revenue.
"We are encouraged by the growth in Q4 2025, driven in particular by the momentum in our Acute Care franchise with ZYNRELEF® and APONVIE®," said Craig Collard, Chief Executive Officer of Heron. "In addition to our revenue growth, we are extremely pleased with the continued progress made across all aspects of our business throughout the past year."
Preliminary Fourth Quarter and Full Year 2025 Updates
Net revenue of approximately $40.5 million for the three months ended December 31, 2025.
ZYNRELEF® net revenue of approximately $12.5 million for the three months ended December 31, 2025.
APONVIE® net revenue of approximately $3.8 million for the three months ended December 31, 2025.
CINVANTI® net revenue of approximately $22.9 million for the three months ended December 31, 2025.
SUSTOL® net revenue of approximately $1.3 million for the three months ended December 31, 2025.
Net revenue of approximately $154.9 million for full-year 2025.
ZYNRELEF® delivered the largest quarter-over-quarter revenue increase within the portfolio in Q4 (up ~35% vs Q3 2025).
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
DrJaguar8
Influential mooer of January
Spread kindness and love. Your actions are your signature—karma is the ink that never fades. Truth walks, lies limp.
22K
Followers
31
Following
358K
Visitors
Follow
ProperMicheleV : reddit is chattering about a potential short squeeze happening here.